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Background: Sex medicine studies have shown that there are sex differences with regard 
to disease characteristics in immune-mediated inflammatory diseases, including psoriasis, in 
immune response and susceptibility to viral infections. We performed a post hoc analysis of the 
Observational Study of infectious events in psoriasis complicated by active psoriatic arthritis 
(SYNERGY) study in patients with psoriatic arthritis (PsA) treated with immunosuppressive 
regimens including cyclosporine, in order to evaluate potential between-sex differences in 
severity of disease and prevalence of viral infections.
Methods: SYNERGY was an observational study conducted in 24 Italian dermatology clinics, 
which included 238 consecutively enrolled patients with PsA, under treatment with immunosup-
pressant regimens including cyclosporin A. In this post hoc analysis, patients’ demographical 
data and clinical characteristics of psoriasis, severity and activity of PsA, prevalence of sero-
positivity for at least one viral infection, and treatments administered for PsA and infections 
were compared between sexes.
Results: A total of 225 patients were evaluated in this post hoc analysis, and 121 (54%) were 
males. Demographic characteristics and concomitant diseases were comparable between sexes. 
Statistically significant sex differences were observed at baseline in Psoriasis Area and Sever-
ity Index score (higher in males), mean number of painful joints, Bath Ankylosing Spondylitis 
Disease Activity Index, and the global activity of disease assessed by patients (all higher in 
females). The percentage of patients with at least one seropositivity detected at baseline, indica-
tive of concomitant or former viral infection, was significantly higher among women than among 
men. No between-sex differences were detected in other measures, at other time points, and 
in treatments. Patients developed no hepatitis B virus or hepatitis C virus reactivation during 
cyclosporine treatment.
Conclusion: Our post hoc sex analysis suggests that women with PsA have a greater articular 
involvement and a higher activity of disease compared to males. Immunosuppressive treatment 
with cyclosporine seems not to increase susceptibility to new infections or infectious reactiva-
tions, with no sex differences.
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Background
Sex medicine aims to investigate how diseases differ between 
men and women in terms of prevalence, manifestation, sever-
ity, therapeutic approach, and prognosis. Sex differences with 
regard to disease characteristics and/or therapeutic approach 
have been reported in immune-mediated inflammatory 
 diseases,  including rheumatoid arthritis, inflammatory bowel 
diseases, and psoriasis.1,2 Marked sex differences have also 
been described in the susceptibility to viral infections, other 
than their incidence and manifestations.3–7 This observation 
may be linked to the fact that sex hormones seem to have 
significant effects on cell-mediated immune responses, as 
shown by several clinical and experimental studies.8–10
Psoriatic arthritis (PsA) is a disabling complication that 
occurs in 6%–39% of psoriatic patients,11 usually following 
skin manifestations and generally characterized by synovitis, 
enthesitis, dactylitis, and spondylitis.12 Patients with PsA 
are often treated with systemic immunosuppressant agents 
(eg, steroids, methotrexate, cyclosporin A [CsA]), which are 
known to increase the risk of new infections or of previous 
infection reactivation, though clinical data are scarce. Regard-
ing anti tumor necrosis factor alpha, data suggest that therapy 
with these agents would appear efficacious and reasonably 
safe in the management of PsA patients with concomitant 
infections.13–17
The Observational Study of infectious events in psoriasis 
complicated by active psoriatic arthritis (SYNERGY) study 
is a cross-sectional and longitudinal (12 months) multi-
center Italian study, involving 238 consecutive patients with 
diagnosis of PsA performed within 8 years from baseline, 
treated from at least 3 months with CsA as monotherapy 
or in combination with one or more systemic drugs. The 
SYNERGY study aimed at assessing: 1) seropositivity for 
former and acute viral infection; 2) effectiveness of CsA 
alone or in combination in a time period of 12 months; and 
3) occurrence of infections or other adverse events during 
the study period.18 The results revealed a high prevalence of 
viral seropositivity – herpes simplex virus 1 (92.3%), her-
pes simplex virus 2 (67%), varicella-zoster virus (95.3%), 
Epstein–Barr virus (89.2%), cytomegalovirus (77.3%), and 
hepatitis B virus (6.1%) – but no viral reactivation during 
the 12-month observation period. However, sex differences 
in seropositivity were not analyzed. Since many differences 
between sexes have been reported in psoriatic patients, in 
terms of epidemiology,19 pattern and burden of disease,20 
but also in immune response as well as susceptibility to viral 
infections,21 it was decided to perform a post hoc analysis to 
evaluate for potential differences between sexes in severity 
of disease, response to treatment, and prevalence of viral 
infections.
Methods
Ethical approval was obtained from the Ethical Committee of 
“G. Pini” Institute of Milan (principal center) and then from 
each participating center and signed informed consent was 
obtained from participating patients. SYNERGY was a cross-
sectional and longitudinal (12 months) observational study, 
conducted in 24 Italian  dermatology clinics, which included 
238 consecutively enrolled patients with PsA. Patients and 
methods of the study are described in detail elsewhere.18
Patients of the SYNERGY study were considered 
evaluable for this post hoc analysis, provided that sex was 
specified. According to the SYNERGY inclusion criteria, 
patients had:
•	 a diagnosis of psoriasis complicated by PsA, according 
to the ClASsification for Psoriatic ARthritis criteria22,23 
performed within 8 years before baseline;
•	 an ongoing treatment with immunosuppressant regimens 
including CsA;
•	 no other form of arthritis besides PsA.
In this analysis, the following variables were com-
pared between sexes at baseline and at 6 and 12 months of 
follow-up:
•	 age and demographical characteristics;
•	 age at diagnosis of psoriasis;
•	 duration of psoriasis;
•	 vaccinations administered;
•	 body surface area;
•	 Psoriasis Area and Severity Index (PASI);
•	 Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI);
•	 global activity of disease;
•	 number of painful and swollen joints;
•	 seropositivity for at least one infection;
•	 treatments for PsA (topical, infiltrations, systemic, ie, 
cyclosporine, methotrexate, biologics);
•	 pharmacological treatments for infections;
•	 adverse events.
The BASDAI is a useful composite measure in spon-
dyloarthropathies and, when the SYNERGY study was 
designed, it was chosen hypothesizing that, since PsA has 
both peripheral and axial clinical manifestations, indices that 
measure only peripheral joint activity, such as the Disease 
Activity Score or the American College of Rheumatology 
response criteria, may not capture sufficient information to 
truly reflect disease activity in PsA.
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Indexes of disease severity and activity were also 
compared between premenopausal and postmenopausal 
women and men of corresponding age, taking as cut off 
50 years, since in Italy, the average age for last period 
is ∼50 years.24
All analyses were performed with SAS version 9.2 (SAS 
Institute Inc., Cary, NC, USA) and Enterprise Guide 4.3 
(SAS Institute Inc., Cary, NC, USA). Descriptive analyses 
were mean and standard deviation (SD), or median and inter-
quartile range. Comparisons were performed by Student’s 
t-test, chi-square test, or Fisher’s exact test, if appropriate. 
The accepted level of significance was set at alpha =0.05. As 
post hoc analyses, all P-value presented are exploratory.
Results
In the SYNERGY study, 238 patients were enrolled, but 
13 patients not fulfilling the inclusion criteria were excluded 
from the analysis.18 Therefore, 225 patients were evaluated in 
this post hoc analysis, of which 121 (54%) were males. The 
distribution of patients according to sex, age, and concomi-
tant diseases at baseline is shown in Table 1; no statistically 
significant differences were observed between males and 
females with respect to these variables (P-values males vs 
females .0.05) as well as in the vaccination profile (2.5% 
of males and 6.7% of females were vaccinated at baseline; 
Fisher’s exact test, P-value =0.2045).
Regarding the severity of psoriasis, PASI score at baseline 
was significantly higher in males compared with females 
(8.0 [SD 7.7] in males vs 5.8 [SD 6.9] in females; t-test, 
P-value =0.028). As shown in Figure 1, in terms of severity 
of PsA at baseline, differences between sexes emerged in the 
mean number of painful (but not of swollen) joints and in 
the global activity of disease, as assessed by patients (but not 
by physicians). Consistently, also the BASDAI at baseline 
was higher in females (44.9 [SD 22.9]) than in males (36.5 
[SD 22.8]; t-test, P-value =0.036). Severity of both psoriasis 
and PsA progressively diminished at 6 and 12 months of 
follow-up, as did differences between sexes, which were no 
longer significant after baseline except for painful joint count 
at 6-month follow-up (4.6 [SD 7.5] in males vs 8.0 [SD 10.1] 
in females; t-test, P-value =0.0162) and swollen joint count 
at 12-month follow-up (0.7 [SD 1.4] in males vs 1.6 [3.4] in 
females; t-test, P-value =0.0358).
As regards infections, the percentage of patients with 
at least one seropositivity detected at baseline, indicative 
of former viral infection, was significantly higher among 
women (68.3%) than among men (53.7%; chi-square 
test, P-value =0.011). As shown by the SYNERGY study, 
none of these patients developed viral or other infectious 
diseases during the 12 month follow-up nor developed 
virus reactivation.
When PASI and BASDAI as indexes of activity of pso-
riasis and PsA, respectively, were analyzed according to 
pre- or postmenopausal status in women and compared with 
men of corresponding age (ie, 50 years and $50 years), 
no statistically significant differences between sexes were 
observed at baseline and at 6 and 12 months of follow-up in 
either age groups (Table 2).
No differences were observed between males and 
females in terms of treatment, either in the percentage of 
treated patients or in the type of medications administered 
(Table 3).
Finally, adverse events during study were reported in eight 
men and seven women (chi-square test, P-value.0.05).
Discussion
Awareness of sex differences in diseases is important among 
professionals. In order to manage such differences, clini-
cians should provide for a highly specialized care, which 
might be particularly useful in psoriasis to provide an equal 
quality of care for women, who have been reported to suffer 
from a higher psychosocial distress and a greater impact on 
quality of life.25,26 It has also been reported that peripheral 
joint involvement and pain are more frequent among female 
Table 1 age, concomitant diseases, and viral status of the 
sYnergY male and female patients at baseline
 Males 
(N=121)
Females 
(N=104)
P-value
age, mean (sD) 48.9 (12.8) 50.8 (12.5) 0.2499
Concomitant diseases (%) 45.5 48.1 0.6942
Cardiovascular diseases 24.8 30.8
Type 1 diabetes 3.3 0
Type 2 diabetes 7.4 3.8
Cerebrovascular diseases 0 1
renal diseases 2.5 1.9
Other diseases 21.5 21.2
Viral positivity (%) 53.7 68.3 0.0105
hBV 5 3.8
hCV 5.8 3.8
Cytomegalovirus 36.4 46.2
hIV 1–2 0 0
hsV 1 42.1 53.8
hsV 2 31.4 37.5
Varicella-zoster virus 17.4 19.2
epstein–Barr virus 32.2 42.3
Abbreviations: hBV, hepatitis B virus; hCV, hepatitis C virus; hIV, human 
immunodeficiency virus; HSV, herpes simplex virus; SD, standard deviation; 
sYnergY, Observational study of infectious events in psoriasis complicated by 
active psoriatic arthritis.
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Figure 1 PasI (A), BasDaI (B), number of painful (C) and swollen joints (D) and indexes of disease activity at each visit (mean ± standard deviation) (E and F), by sex.
Abbreviations: BasDaI, Bath ankylosing spondylitis Disease activity Index; PasI, Psoriasis area and severity Index.
Table 2 PasI and BasDaI in pre- and postmenopausal women compared to age-matched men at each study time point
PASI mean (SD) BASDAI mean (SD)
Baseline 6 months 12 months Baseline 6 months 12 months
N=50 N=38 N=37 N=23 N=15 N=16
Premenopausal women 5.9 (7.2) 3.0 (4.4) 2.3 (4.0) 36.6 (22.3) 28.5 (25.0) 26.2 (29.9)
N=64 N=48 N=50 N=40 N=23 N=19
Men aged 50 years 8.2 (7.7) 4.9 (6.9) 4.1 (6.4) 31.6 (22.8) 28.6 (27.3) 23.9 (23.6)
P-value 0.1047 0.1383 0.1147 0.3994 0.9944 0.7992
N=53 N=46 N=42 N=36 N=26 N=21
Postmenopausal women 5.7 (6.6) 3.1 (5.1) 2.9 (4.7) 50.3 (21.9) 38.1 (23.3) 28.5 (24.1)
N=56 N=45 N=45 N=34 N=22 N=16
Men aged $50 years 7.7 (7.8) 3.6 (3.8) 2.8 (4.1) 42.2 (21.7) 30.0 (26.1) 21.0 (15.6)
P-value 0.1487 0.5467 0.9591 0.1279 0.2629 0.2825
Abbreviations: BasDaI, Bath ankylosing spondylitis Disease activity Index; PasI, Psoriasis area severity Index; sD, standard deviation.
psoriatic patients than among male patients.27,28 Another 
recently published article confirmed the greater peripheral 
involvement in women with PsA (with more frequent polyar-
thritis) as well as greater physical functional impairment.29 In 
our analysis, consistently, a significantly greater number of 
painful joints as well as greater patients’ assessed activity of 
PsA were observed in female compared to male patients. On 
the other hand, slightly higher PASI values were observed in 
men compared to women at baseline. All the aforementioned 
sex differences disappeared at follow-up visits, but this may be 
easily explained by the overall progressive improvement of the 
disease during the study, likely due to participation in the trial 
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per se, sustained pharmacological treatment, and increased 
use of biologics in combination with CsA during the course 
of the study, as reported in the SYNERGY paper.18
Concerning the pattern of infections, interestingly a 
higher percentage of women had seropositivity for at least one 
viral infection. The explanation for this difference is not clear, 
but might be related to the greater humoral immune responses 
of females to viral antigens, reported by many authors.30–33 
The reason for these differences in susceptibility to infections 
between males and females has been reported to be multifac-
torial. The primary cause is thought to be due to differences 
induced by sex hormones and their effects on gene expression 
as well as the immune system, but may also be due to innate 
physiological differences between males and females. It has 
also been suggested that there may be an interaction between 
sex-specific immune differences and the specific immune 
response to individual microbes. Menopausal status seems 
not to affect the severity of disease among women, since 
stratifying the study population by age (50 years or $50 
years) seems to flatten differences between sexes. This might 
be due to the lower sample size in each group.
An important aspect, already pointed out by the SYN-
ERGY study, is that treatment with CsA alone or combined 
with other immunosuppressant seems not to favor the 
reactivation of severe viral infections in previously infected 
patients, with no difference between females and males, 
even though men have been reported to have an  underlying 
immunosuppressed condition compared to women, due 
to the immunosuppressive effects of male steroidal sex 
hormones.34–36
Finally, the observation of no difference in the therapeutic 
approach between sexes is consistent with the findings of the 
previously conducted MetaGeM analysis of the PSYCHAE 
study,37 confirming that Italian physicians do not adopt 
different approaches between sexes, even though articular 
involvement, activity of disease, and psychological distress 
have been reported to be worse in females.
We are aware that this paper has a limitation to be a post 
hoc analysis of a study, not specifically aimed at assessing 
sex differences. Thus, the sample size was not calculated 
on this specific hypothesis and furthermore, data collection 
may have missed relevant information. Due to the relatively 
small sample size, we could not further split the male–female 
patient populations by CsA monotherapy or combination 
therapy, and this may be considered another limitation, since 
the potential interactions with concomitant medications 
have not been addressed. On the other hand, because of the 
exploratory aim of these analyses, the significance threshold 
was set to 0.05 and not corrected.38
Conclusion
The present post hoc sex analysis of the SYNERGY study 
shows a greater articular involvement and a higher self-
assessed disease activity in female patients with PsA as 
compared to males, which, together with the heavier psy-
chological distress reported in the PSYCHAE study, further 
suggest that psoriatic women may deserve more attention and 
probably a slightly different therapeutic approach, including 
psychological support. Moreover, our analysis shows a higher 
percentage of viral seropositivities among women. Finally, 
cyclosporine treatment seems not to induce hepatitis B virus 
or hepatitis C virus reactivation in either sex.
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